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and approPurpose: The justification for partial breast radiotherapy after breast conservation surgery assumes that ipsilat-
eral breast tumor relapses (IBTR) outside the index quadrant are mostly new primary (NP) tumors that develop
despite radiotherapy.We tested the hypothesis that whole-breast radiotherapy (WBRT) is ineffective in preventing
NP by comparing development rates in irradiated and contralateral breasts after tumor excision and WBRT.
Methods andMaterials:We retrospectively reviewed 1,410 womenwith breast cancer who were entered into a pro-
spective randomized trial of radiotherapy fractionation and monitored annually for ipsilateral breast tumor re-
lapses (IBTR) and contralateral breast cancer (CLBC). Cases of IBTR were classified into local recurrence
(LR) or NP tumors based on location and histology and were subdivided as definite or likely depending on clinical
data. Rates of ipsilateral NP and CLBC were compared over a 15-year period of follow-up.
Results: At a median follow-up of 10.1 years, there were 150 documented cases of IBTR: 118 (79%) cases were
definite or likely LR; 27 (18%) cases were definite or likely NP; and 5 (3%) cases could not be classified. There
were 71 cases of CLBC. The crude proportion of definite-plus-likely NP was 1.9% (27/1,410) patients compared
with 5% (71/1,410) CLBC patients. Cumulative incidence rates at 5, 10, and 15 years were 0.8%, 2.0%, and
3.5%, respectively, for definite-plus-likely NP and 2.4%, 5.8%, and 7.9%, respectively for CLBC, suggesting a dif-
ference in the rates of NP and CLBC.
Conclusions: This analysis suggests that WBRTreduces the rate of ipsilateral NP tumors. The late presentation of
NP has implications for the reporting of trials that are testing partial breast radiotherapy.  2011 Elsevier Inc.
Breast cancer, Ipsilateral, Contralateral, Relapse, Radiotherapy.INTRODUCTION
The rationale for partial breast radiotherapy (PBRT) after
breast conservation surgery for early breast cancer includes
the assumption that most ipsilateral breast tumor relapses
(IBTR) developing outside the index quadrant are new pri-
mary (NP) tumors that are not prevented by radiotherapy
(1–3). Several phase I and II studies evaluating accelerated
PBRT have reported promising early results, with few local
tumor relapses, while maintaining excellent cosmetic out-
comes and minimum toxicity (4–7). Currently, PBRT for
early breast cancer is being investigated in several phase III
randomized studies (8–12). However, evidence that whole-An online CME test for this article can be taken at http://
.org under Continuing Education.
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19breast radiotherapy (WBRT) has little or no effect on the
rate of ipsilateral NP tumors is not particularly robust, and
a number of recent retrospective studies with long follow-
up periods suggest a significant therapeutic effect (13–16).
In order to test for such an effect, it is necessary to apply cri-
teria that distinguish between local recurrences (LR) and NP
tumors. The purpose of this study was to test the hypothesis
that WBRT reduces the rate of ipsilateral NP, which otherwise
occur at a rate comparable to that of contralateral breast cancer
(CLBC). The research plan involved (i) classifying IBTR in
breast cancer patients treated with breast-conserving therapy
as LR or NP tumors based on location and histology of theThe trial from which data were extracted was funded in part by
Marks and Spencer Plc. The Institute of Cancer Research Clinical
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ing the rates of ipsilateral NP with that in the opposite breast.
METHODS AND MATERIALS
Study design
A retrospective review was undertaken of the medical records of
women with early breast cancer treated with conservative surgery
and WBRT at the Royal Marsden Hospital and Gloucestershire On-
cology Centre between 1986 and 1998 in the context of a prospective
randomized trial of radiotherapy fractionation (17, 18). The original
trial was approved by the local ethics committees, and this review
was approved by the audit committee at the Royal Marsden NHS
Foundation Trust.
Original trial
The aim of the original study was to test the effects of radiother-
apy fractions of >2 Gy on late normal tissue responses after tumour
excision and WBRT. Patients under 75 years of age at presentation
with operable invasive breast cancer (T1–T3 N0–N1 M0) requiring
radiotherapy were eligible for the original clinical trial if they had
breast-conserving surgery and complete macroscopic resection of
invasive carcinoma.
Patients were randomized to three alternative dose schedules (50
Gy in 25 fractions over 5 weeks [control], 42.9 Gy in 13 fractions
five times per fortnight over 5 weeks, and 39 Gy in 15 fractions
five times per fortnight over 5 weeks) at a ratio of 1:1:1. Patients
were stratified by treatment centre and by whether microscopic
foci of invasive disease was present at or <3 mm to the nearest sur-
gical margin. Recommendations for adjuvant systemic therapy were
not specified in the protocol and developed over the accrual period
according to changes in routine local practice. Patient cases were re-
viewed at 3-month intervals for the first 3 years, 6-month intervals to
5 years, and annually thereafter. Physician assessments were pro-
spectively recorded annually on a trial pro forma report. IBTR
was recorded onto the pro forma report pictorially to show the quad-
rant of relapse in relation to the location of the original tumour. His-
tology of the relapse was also recorded on the pro forma record if
available. CLBC and metastases were also recorded prospectively.
Patients were followed up routinely biannually for the first 5 years
with annual mammography and yearly thereafter with biennial
mammography.
The primary endpoint was late change in breast appearance com-
pared to postsurgical appearance. Secondary endpoints included
palpable breast induration (fibrosis) and ipsilateral tumour recur-
rence.
Classification of ipsilateral relapse
For the present study, trial case report forms of all patients re-
corded were reviewed as having local relapse. All patients with an
IBTR were identified, and a further review of clinical, mammo-
graphic, and pathology data was undertaken to classify relapses as
either LR or NP. Metastatic disease at time of local relapse was
also recorded. We considered only the first local relapse in patients
who developed more than one ipsilateral relapse. Demographic and
clinical data of each patient with an IBTR were recorded. These data
included patient’s age at randomization, tumour size and location at
original diagnosis, nodal status at original diagnosis, histology of
original tumour and of relapse, resection margin status of original
tumour (complete, marginal, incomplete, or unknown) estrogen
and progesterone receptor status (if available), adjuvant chemother-
apy and/or hormonal therapy, location of relapse relative to primarytumour bed, and method of detection of original tumour and relapse.
The location of the original tumour and the relapse was determined
by review of radiotherapy records and surgical and clinical notes.
Radiotherapy and follow-up data were also recorded.
After clinical and pathological data were reviewed, IBTR was
classified as either NP or LR, and each category was subclassified
as ‘‘definite’’ or ‘‘likely’’, depending on the strength of the collated
evidence. An IBTR was classified as definite LR if it presented in the
same quadrant as the original primary, determined to be the same
histological type, and was the same or higher grade. IBTR was clas-
sified as definite NP if it was of a different histological type, a lower
grade, and located in a different quadrant than the original primary.
Tumour grade was incorporated into histological type. IBTR was
classified as likely LR or likely NP based on the available evidence
when any of the above data were incomplete or inconclusive. IBTR
were classified as unknown if there was no information on location
and histology.
The number of CLBC was recorded from the trial data, as each
CLBC was recorded prospectively onto the case report form.Statistical analysis
Descriptive statistics were used for patient and tumour character-
istics. Survival analysis methods were used to analyze the events
(LR, NP, and CLBC). Time to event was calculated as the time
from randomization to first occurrence of the event. For the analysis
of time to each event, patients who were event-free by the time of
analysis or dead or lost to follow-up prior to the event were cen-
sored. In addition, for the analysis of time to NP, patients who
were diagnosed with LR prior to NP were also censored as it was
thought that an LR could potentially preclude or alter the probability
of observing an NP. Likewise, the NP was treated as a competing
risk for LR. Cumulative incidence rates with 95% confidence inter-
vals (CI) were estimated for CLBC, using the Kaplan-Meier
method, and for LR and NP, using a method accounting for the com-
peting risk (19). Data analyses were performed using Stata version
10.1 software.RESULTS
All 1,410 women randomized into the radiotherapy frac-
tionation trial between 1986 and 1998 were considered for
the study. Baseline characteristics have been described previ-
ously (17) and are summarized in Table 1. The median fol-
low-up was 10.1 years and 1,176 (99.0%), 534 (53.4%),
and 69 (9.9%) patients were still on follow-up at 5, 10, and
15 years, respectively.
There were 150 documented cases of IBTR and 71 cases of
CLBC. The median age at randomization of women who de-
veloped IBTR was 50 years (interquartile range [IQR], 42–58
years). The median time to relapse from randomization was
41 months (IQR, 24–70 months). Fifty-nine (39%) patients
had metastatic disease at the time of IBTR, of whom 39/59
(66%) patients had definite or likely LR. The classification
of IBTR was as follows: definite LR, 85 (57%) patients;
likely LR, 33(22%) patients; definite NP, 12 (8%) patients;
likely NP, 15 (10%) patients; and unknown, 5 (3%) patients
(Table 2). The data on which 150 IBTR were classified as
definite or likely, LR or NP, is illustrated in Fig. 1. Cumula-
tive incidence rates at 5, 10, and 15 years were 6.7, 8.9, and
Table 1. Demographic and clinical characteristics of
randomized patients
Patient characteristic
Number of patients
(% of n [1,410])
Age at randomization
20–29 9 (0.9)
30–39 98 (7.0)
40–49 316 (22.4)
50–59 503 (35.7)
60–69 425 (30.1)
70–79 59 (4.2)
Breast size (from photographs)
Small 186 (13.2)
Medium 952 (67.5)
Large 203 (14.4)
Not known 69 (4.9)
Surgical deficit (from photographs)
Small 845 (59.9)
Medium 415 (29.4)
Large 76 (5.4)
Not known 74 (5.2)
cT stage
T0 59 (4.2)
T1 749 (53.1)
T2 575 (40.8)
T3 22 (1.6)
T4 2 (0.1)
TX 3 (0.2)
cN stage
N0 1,187 (84.7)
N1 219 (15.5)
N2 3 (0.2)
NX 1 (0.1)
Number of nodes pathologically involved
0 564 (67.3)
1–3 202 (24.1)
4+ 72 (8.6)
No axillary surgery* 572 (40.6)
Adjuvant treatment
None 289 (20.5)
Tamoxifen only 918 (65.1)
Chemotherapy only 40 (2.8)
Tamoxifen plus chemotherapy 156 (11.1)
Other 7 (0.5)
Axillary/SCF treatment
None 337 (23.9)
Axillary/SCF RT, no axillary surgery 231 (16.4)
Surgery, no RT 782 (55.5)
Surgery and SCF RT 59 (4.2)
Not known 1 (0.1)
Breast boost
Randomized to no boost 359 (25.5)
Randomized to boost 364 (25.8)
Non-randomized boost given 687 (48.7)
Abbreviations: SCF = supraclavicular fossa; RT = radiotherapy;
cT = clinical T stage; cN = clinical node stage.
* cN0 and over 50 years of age.
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7.9 for CLBC, respectively (Table 3).
The median (IQR) age at randomization of women who
developed CLBC was 55 (range, 45–61) years. Fifteen cases
of CLBC also had IBTR (definite LR, 8 likely; LR, 4; definite
NP, 1; likely NP, 2). The number of CLBC (71 cases) was atleast two and a half times the number of ipsilateral NP (12
definite plus 15 likely). Even if all 33 likely LR cases were
counted as NP, the total (60 cases) was still less than the num-
ber of CLBC. Figures 2 and 3 illustrate the cumulative inci-
dence rates for definite NP, definite-plus-likely NP and
CLBC. The inference is that radiation has reduced the num-
ber of ipsilateral NP tumors.DISCUSSION
This study is based on breast-conserving surgery and
WBRT associated with a 10-year Kaplan-Meier event rate
of IBTR of 12%, which is consistent with that of other con-
temporary series (20, 21). The number of ipsilateral NP
was less than half the number of CLBC (27 compared to
71). It is not possible to explain the discrepancy in terms of
a smaller volume of ipsilateral breast tissue at risk following
primary surgery (where we would expect the reduction in
breast tissue to be around 10% to 25%) nor in terms of mis-
classification of NP. The only plausible explanation is that
WBRT has a protective effect against NP tumors.
The 5-year risk of IBTR after breast-preserving surgery
has previously been reported as 5 to 10% (15, 22), corre-
sponding to an annual risk of 1 to 2% (15). Several studies
have attempted to differentiate between true recurrences
and new primaries (20, 23–25), from which common themes
are apparent: the majority of IBTR are LR, which tend to
occur earlier, metastasize earlier and more often, and have
a shorter overall and disease-free survival than NP. In our se-
ries, 59 (39%) patients had metastatic disease at relapse, of
whom 39/59 (66%) patients had LR, consistent with the re-
ported association between LR and risk of distant relapse
(21, 26). In addition, NP is associated more often than LR
in the literature with contralateral breast cancer. The median
times to relapse for cases of definite and likely LR (37 and 35
months, respectively) in our series were also shorter than for
definite and likely NP (86 and 63 months, respectively), in
keeping with results from previous series (20, 23–25) and
supporting our attributions of IBTR.
The number of CLBC events was 71 (5%), corresponding
to an annual rate of 0.56% (71/1,2766.56 women years 
100). Although this rate is influenced by patient age and ad-
juvant endocrine therapies, it is comparable to published rates
of 0.5% to 1% per year in other series (27, 28) and indepen-
dent of the type of primary surgery (29, 30). Where under-re-
porting is considered a potential source of bias, CLBC is
probably more likely to be under-reported in trial datasets
than IBTR, so this is unlikely to account for the excess of
CLBC compared to ipsilateral NP. Although adjuvant sys-
temic therapies, including endocrine and cytotoxic therapies,
reduce the incidence of new primary tumors (14, 31), there is
no a priori reason to think that this effect will be greater on
the ipsilateral than on the contralateral breast. Finally,
although the risk of CLBC is increased after radiotherapy,
there is no reason to believe that this risk is proportionately
greater than the risk of radiation-induced cancers in the
ipsilateral breast.
Table 2. Classification of 150 IBTR cases
Characteristics
No. of definite
LR (n = 85)
No. of definite
NP (n = 12)
Likely
LR (n = 33)
Likely
NP (n = 15)
Unknown
(n = 5)
Median age at randomization
(IRQ range in years)
49 (42–57) 50 (42–52.5) 49 (45–59) 55 (42–59) 57 (55–60)
Histology at initial diagnosis of breast cancer
Ductal 67 10 27 12 4
Lobular 4 0 2 1 0
Other 11 1 2 1 0
Mixed 2 0 2 0 0
Comedo 0 1 0 0 1
Squamous 1 0 0 0 0
Unknown 0 0 0 1 0
Pathological tumor stage at initial diagnosis
Tis 2 0 0 0 1
T1 24 5 15 7 2
T2 58 7 14 8 2
T3 1 0 3 0 0
Unknown 0 0 1 0 0
Nodal status at initial diagnosis
N0 65 9 28 12 4
N1 20 3 5 3 1
Resection margin status
Complete 47 5 18 10 3
Marginal 7 3 3 2 0
Incomplete 22 2 9 3 1
Unknown 9 2 3 0 1
Time from randomization to IBTR (median IRQ range in months)
37 (23–52) 86 (53–122) 35 (23–70) 63 (43–92) 37 (29–54)
Metastatic disease at IBTR
Yes 39 2 13 2 3
No 39 10 15 12 1
Unknown 7 0 5 1 1
Abbreviations: Comedo = comedogenic; Tis = Carcinoma in situ.
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retrospective analysis of 1,990 women with early breast can-
cer treated with conservative surgery and whole-breast irradi-
ation and followed for a median 6.6 (range, 0.1–20.4) years
(13). The 15-year rate of ipsilateral NP was half the rate ofRelapse
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fication of IBTR.
Table 3. Cumulative incidence rates for LR, NP, and CLBC
Type of event
% of incidence (95% CI) at:
5 years 10 years 15 years Total events
LR 5.0 (3.9–6.3) 6.5 (5.2–7.9) 8.7 (6.2–11.6) 85
LR plus likely LR 6.7 (5.5–8.2) 8.9 (7.4–10.6) 11.8 (9.1–14.9) 118
NP 0.2 (0.1–0.6) 0.8 (0.4–1.5) 1.9 (0.9–3.7) 12
NP plus likely NP 0.8 (0.4–1.4) 2.0 (1.3–2.9) 3.5 (2.1–5.4) 27
CLBC 2.4 (1.7–3.4) 5.8 (4.6–7.4) 7.9 (5.9–10.4) 71
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Smith et al. (20) classified 130 cases of IBTR in 1,152
patients as NP (70) or LR (60) based on location, histology,
and/or flow cytometry over a mean follow-up of 14.2 years
(0.13 years). The rates of LR and NP at 15 years were
6.8% and 13.1%, respectively. The NP rate was reported as
similar to the CLBC rate. However, there are important
points to consider when interpreting these data. NP and
CLBC rates may have been higher due to the fact that 8 of
70 IBTR cases classified as NP were BRCA1 or BRCA2 car-
riers, and 5 of these women developed CLBC. Importantly,
all IBTR that appeared in a separate quadrant or were dis-
tinctly removed from the original primary were classified
as NP. The authors acknowledged that some of these tumors
may have represented multicentric disease that was not fully
eradicated by radiation therapy. It is therefore likely that
some NP tumors were misclassified. An important difference
between that study and ours is the use of systemic treatment:
in the study by Smith et al. (20), 261/1,152 and 267/1,152
patients received adjuvant chemotherapy and hormone ther-
apy, respectively, compared with 918/1,410 patients who
received adjuvant hormones, 40/1,410 patients who received
chemotherapy only, and 156/1,410 patients who received
both in our cohort. The greater number of patients who re-
ceived systemic therapy in our cohort may account partly
for the lower rates of NP and CLBC.
The Milan I trial (22) reported similar NP and CLBC rates
in 579 women treated with quadrantectomy and randomized0%
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Fig. 2. Cumulative incidence rates with 95% CI for definite NP
(dashed lines) versus CLBC (solid lines).to receive breast radiotherapy or not. However, the absolute
numbers of NP and CLBC reported were small (10 and 22 pa-
tients, respectively). The similarity in NP and CLBC rates
was noted in the group of patients treated with quadrantec-
tomy without radiotherapy (n = 273 patients). In the group
of women who received radiotherapy after quadrantectomy
(n = 294), there were 2 NP events and 10 CLBC events, cor-
responding to 2/294 (0.6%) and 10/294 (3.4%) patients, re-
spectively. This is more in keeping with our findings and
consistent with a radiotherapy effect against NP. In the group
not treated with radiotherapy, NP and CLBC rates were 2.9%
(8/273) and 4.4% (12/273), respectively. An earlier study by
Veronesi et al. (32) reported 19 NP and 45 CLBC events in
1,232 cases of early breast cancer treated with breast-con-
serving surgery and radiotherapy (1.5% and 3.7%, respec-
tively), also in keeping with our results.
It is important to note that the analytical methods em-
ployed by these studies did not account for competing risks,
which could make a difference as the competing risk event
rates in their cases were higher. Our approach took into con-
sideration competing risks, although, ultimately, a big differ-
ence compared to the Kaplan-Meier approach was not noted
as the competing risk event rate was very low.
Assuming completeness of reporting IBTR and CLBC, the
only way our analysis leads to a wrong conclusion is if a sub-
stantial proportion of ipsilateral LR cases have been misclas-
sified. It would require all 33 likely LR to be reclassified as
NP and added to the total of 12 definite and 15 likely NP.0%
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Fig. 3. Cumulative incidence rates with 95% CI for definite-plus-
likely (NP + likely NP) (dashed lines) versus CLBC (solid lines).
24 I. J. Radiation Oncology d Biology d Physics Volume 79, Number 1, 2011Even then, there would be 11 fewer NP than CLBC, a discrep-
ancy that might be explained by the loss of breast tissue due
to primary surgery and/or misclassification of a minority of
definite LR. In future studies, molecular analyses may help
identify the subset of IBTR that are NP on the basis of clonal
differences. There have already been some clone studies
looking at IBTR, ipsilateral relapses, and distant metastases
and the relationships between them (33, 34). Meanwhile, it
is fair to say that there is fairly strong evidence that what
we currently classify as NP are responsive to radiotherapy.CONCLUSIONS
This study suggests that WBRT after breast-conserving
surgery for early breast cancer reduces the rate of ipsilateral
NP tumors. If true, the results from this study lead to a predic-
tion that current trials of PBRT will eventually record higher
rates of IBTR after partial-breast than after whole-breast RT.
Longer follow-up and robust classification of IBTR cases
into LR and NP tumors are required to reflect the true rate
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